Effects of renal denervation on blood pressures in patients with hypertension: a systematic review and meta-analysis of randomized sham-controlled trials
Top Cited Papers
- 17 October 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Hypertension Research
- Vol. 45 (2), 210-220
- https://doi.org/10.1038/s41440-021-00761-8
Abstract
The efficacy of renal denervation has been controversial, but recent randomized sham-controlled trials demonstrated significant blood pressure reductions after renal denervation in patients with hypertension. We conducted a systematic review and updated meta-analysis to evaluate the effects of renal denervation on ambulatory and office blood pressures in patients with hypertension. Databases were searched up to 25 May 2021 to identify randomized, sham-controlled trials of renal denervation. The primary endpoint was change in 24 h ambulatory systolic blood pressure with renal denervation versus sham control. The secondary endpoints were daytime and nighttime systolic blood pressure, and office systolic blood pressure. A sub-analysis determined outcomes by medication, procedure, and device. From nine trials, 1555 patients with hypertension were randomized to undergo renal denervation (n = 885) or a sham procedure (n = 670). At 2–6 months after treatment, renal denervation significantly reduced 24 h ambulatory systolic blood pressure by 3.31 mmHg (95% confidence interval: −4.69, −1.94) compared with the sham procedure (p < 0.001). Renal denervation also reduced daytime SBP by 3.53 mmHg (−5.28, −1.78; p < 0.001), nighttime SBP by 3.20 mmHg (−5.46, −0.94; p = 0.006), and office SBP by 5.25 mmHg (−7.09, −3.40; p < 0.001) versus the sham control group. There were no significant differences in the magnitude of blood pressure reduction between first- and second-generation trials, between devices, or with or without medication. These data from randomized sham-controlled trials showed that renal denervation significantly reduced all blood pressure metrics in medicated or unmedicated patients with hypertension, including resistant/uncontrolled hypertension. Future trials should investigate the long-term efficacy and safety of renal denervation.Keywords
This publication has 61 references indexed in Scilit:
- Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 studyThe Lancet, 2013
- First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertensionEuroIntervention, 2012
- Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trialThe Lancet, 2010
- Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or treated with immunomodulatory agentsMediterranean Journal of Hematology and Infectious Diseases, 2010
- Superiority of Ambulatory Over Clinic Blood Pressure Measurement in Predicting MortalityHypertension, 2005
- Prognostic Value of Ambulatory and Home Blood Pressures Compared With Office Blood Pressure in the General PopulationJournal of the American College of Cardiology, 2005
- Global burden of hypertension: analysis of worldwide dataThe Lancet, 2005
- Prognostic Value of Ambulatory Blood-Pressure Recordings in Patients with Treated HypertensionThe New England Journal of Medicine, 2003
- Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studiesThe Lancet, 2002
- SPLANCHNICECTOMY FOR ESSENTIAL HYPERTENSIONJournal of the American Medical Association, 1953